<DOC>
	<DOCNO>NCT02546661</DOCNO>
	<brief_summary>This open label , multi-drug , biomarker-directed , multi-centre , multi-arm , randomised Phase 1b study patient muscle invasive bladder cancer ( urothelial ) progress prior treatment . This study modular design , allow evaluation safety , tolerability , pharmacokinetics anti-tumour activity multiple agent monotherapy combination different novel anti-cancer agent patient muscle invasive bladder cancer . The study consist number study module ( substudies ) , evaluate safety tolerability specific agent combination .</brief_summary>
	<brief_title>Open-Label , Randomised , Multi-Drug , Biomarker-Directed , Phase 1b Study Pts w/ Muscle Invasive Bladder Cancer</brief_title>
	<detailed_description>This open label , multi-drug , biomarker-directed , multi-centre , multi-arm , randomised Phase 1b study patient muscle invasive bladder cancer ( urothelial ) progress prior treatment . This study modular design , allow evaluation safety , tolerability , pharmacokinetics anti-tumour activity multiple agent monotherapy combination different novel anti-cancer agent patient muscle invasive bladder cancer . The study consist number study module ( sub-studies ) , evaluate safety tolerability specific agent combination patient whose tumour express specific mutation relevant molecule investigation whose disease progress follow prior therapy . The allocation patient specific module depend specific eligible mutation identify tumour . Module A include AZD4547 monotherapy arm durvalumab + AZD4547 combination therapy arm . Patients receive AZD4547 monotherapy option cross durvalumab monotherapy treatment point objective progression . Module A investigate safety tolerability durvalumab give intravenously , combination AZD4547 give orally select patient muscle invasive bladder cancer tumours fibroblast growth factor receptor mutation fibroblast growth factor receptor fusion whose disease progress follow prior therapy . Specifically follow fibroblast growth factor receptor 3 activate mutation eligible , R248C , S249C , G370C , Y373C , S371C , G3780R , fibroblast growth factor receptor 1 , 2 , 3 gene fusion result removal c-terminal fibroblast growth factor receptor encode intact tyrosine kinase domain , example fibroblast growth factor receptor 3-transforming acidic coiled-coil 3 fusion identify bladder cancer glioblastoma . Module A evaluate durvalumab + AZD4547 combination dose ( ) clinical evaluation ass safety , tolerability efficacy AZD4547 give orally select patient muscle invasive bladder cancer progress follow prior therapy . In combination arm , maximum tolerate dose defined dose-limiting toxicity . An expansion cohort ( ) Module A enroll additional patient explore safety , tolerability , pharmacokinetics biological activity select AZD4547 plus durvalumab dose ( ) . Patients receive AZD4547 monotherapy option cross durvalumab monotherapy point objective progression long investigator believe patient 's interest continue MEDI4736 monotherapy . Module B evaluate durvalumab + olaparib combination dose ( ) confirm safety tolerability durvalumab give intravenously combination olaparib ( AZD2281 ) . Olaparib give orally select patient muscle invasion bladder cancer ( MIBC ) whose tumor deleterious mutation , deletion truncations one panel homologous recombination repair ( HRR ) gene , whose disease progress follow prior therapy . Module C evaluate durvalumab + AZD1775 combination dos ( ) confirm safety tolerability durvalumab give intravenously , combination AZD1775 give orally select patient MIBC whose tumour mutation gene involve cell cycle regulation ( eg , loss either retinoblastoma 1 cyclin-dependent kinase inhibitor 2A amplification cyclin E1 MYC family gene ) . Module D evaluate durvalumab monotherapy treatment confirm safety tolerability durvalumab give intravenously monotherapy patient MIBC qualify Modules A , B C. This sub-study restricted PD-L1 define sub-population intend perform retrospective analysis PD-L1 patient positive PD-L1 status include monotherapy module . Module E evaluate safety tolerability durvalumab give intravenously , combination vistusertib ( AZD2014 ) give orally patient MIBC whose disease progress follow prior therapy . Patients enter sub study whose tumour show mutation would eligible study module , exception follow mutation potential respond mTOR inhibitor : RICTOR amplification , TSC1/2 mutation .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Inclusion Criteria Modules : 1 . M/F ≥18 2 . Metastatic MIBC 3 . 2nd/3rd line 4 . Failed adjuvant/neoadjuvant chemotherapy &lt; 1 yr 5 . 1 lesion ≥10 mm baseline long diameter suitable accurate repeat measurement 7. WHO perf . status 01 Specific Module A : 1 . M/F ≥25 2 . Confirmation FGFR3 mutation FGFR fusion Specific Module B : 1 . Hgb ≥ 10 g/dL 2 . Deleterious mutation , deletion truncation HRR gene Specific Module C : 1 . Tumour harbours deletion inactivate mutation CDKN2A RB1 gene and/or amplification CCNE1 , MYC , MYCL MYCN gene Specific Module E : 1 . Contraception must sustain throughout treatment vistusertib 16 wks last dose Exclusion Criteria Modules : 1 . Immunotherapy , chemotherapy , anticancer agent , radiotherapy &lt; 4 wks , radiotherapy palliation &lt; 2 wks , study drug &lt; 30 day . 2 . Major surgery &lt; 4 wk 3 . Unresolved toxicity prior therapy 4 . Concurrent chemotherapy , immunotherapy , biologic hormonal therapy 5 . Immunosuppressive drug &lt; 28 day 6 . Any following : Autoimmune disease ≤2 yr IBD Primary immunodeficiency Organ transplant require immunosuppressive 7 . Spinal cord compression brain metastasis , treat stable &amp; require steroid least 4 week 8 . Severe uncontrolled systemic disease 9 . Any following : Mean QTc ≥470 m Abnormalities rest ECG Factors increase risk QTc prolongation arrhythmia Uncontrolled hypertension hypotension LVEF &lt; 55 % Atrial fibrillation NYHA Grade IIIV Severe valvular disease Uncontrolled angina Stroke/TIA &lt; 6 month Acute coronary syndrome &lt; 6 month 10 . Any following laboratory value : ANC &lt; 1.5x10 ( exp9 ) /L Platelets &lt; 100x10 ( exp9 ) /L Hgb &lt; 9.0 g/dL ALT &gt; 2.5xULN &gt; 5xULN liver mets Total bilirubin &gt; 1.5 time ULN Gilbert 's disease ≥2×ULN Creatinine &gt; 1.5xULN concurrent creatinine clearance &lt; 50 mL/min Corrected CA &gt; ULN PO4 &gt; ULN 11 . History tuberculosis 12 . Live attenuate vaccination &lt; 30 day For Module A : 1 . Prior exposure : Nitrosourea mitomycin C &lt; 6 week Agent FGFR inhibition primary pharmacology AZD4547 Potent inhibitors/inducers CYP3A4 , inhibitor CYP2D6 substrates CYP3A4 &lt; 2 wks 2 . Ophthalmological criterion : RPED Laser treatment intraocular injection macular degeneration Agerelated macular degeneration Retinal vein occlusion Retinal degenerative disease Any clinically relevant chorioretinal defect 3 . Refractory nausea/vomiting , chronic GI disease , previous bowel resection For Module B : 1 . Transfusion &lt; 120 day 2 . Concurrent medication strong inhibitor cytochrome P450 ( CYP ) 3A ( CYP3A ) strong inducer CYP3A4 . 3 . Previous treatment PARP inhibitor , include olaparib 4 . Patients history MDS AML For Module C : 1 . Prior exposure follow : Nitrosourea mitomycin C &lt; 6 wks Any agent Wee1 inhibition primary pharmacology Prior treatment AZD1775 2 . Any drug product know sensitive CYP3A4 substrates CYP3A4 substrate narrow therapeutic index , moderate strong inhibitors/inducers CYP3A4 3 . Herbal preparation 4 . Refractory nausea vomit chronic GI diseases 5 . Cardiac disease &lt; 6 month For Module E : 1 . Minor surgery &lt; 14 day first dose 2 . Exposure specific substrates OATP1B1 , OATP1B3 , MATE1 MATE2K &lt; 5x halflife ) treatment . Exposure strong/moderate inhibitor inducer CYP3A4/5 , Pgp ( MDR1 ) BRCP take within washout period first dose 3 . Haemopoietic growth factor ( filgrastim , sargramostim , GMCSF ) &lt; 14 day prior receive treatment 4 . Other mTOR inhibitor 5 . Renal disease renal tubular acidosis 6 . Uncontrolled Type 1 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AZD4547</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>Olaparib</keyword>
	<keyword>AZD2281</keyword>
	<keyword>AZD1775</keyword>
	<keyword>Muscle invasive bladder cancer</keyword>
	<keyword>MIBC</keyword>
	<keyword>BISCAY</keyword>
	<keyword>AZD2014</keyword>
	<keyword>Vistusertib</keyword>
</DOC>